Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

MedMen Reports Record Q4 Revenues amid Pandemic Recovery

Stock MarketsSep 27, 2021 07:30PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. MedMen Reports Record Q4 Revenues amid Pandemic Recovery

MedMen (MMEN) is a U.S. cannabis producer and retailer which operates in multiple states.

The company reported 55.4% year-over-year revenue growth in Q4 2021, as its cannabis shops reopened post-COVID-19. The company is also opening new shops and expanding grow facilities.

The company’s stock price has seen a lot of action over the last 12 months, and currently sits at C$0.37.

I am bullish on the stock, and feel that it will undergo more uptrend as revenues continue to grow, and more stores are opened. (See MedMen stock charts on TipRanks)


The company operates 24 cannabis retail shops. MedMen has locations in California, Nevada, Illinois, Arizona, and Florida. MedMen has four retail shops in New York, which it is discontinuing.

The company also operates grow and manufacturing facilities in California, Nevada, Arizona, and Florida. It has plans of adding new stores in Illinois, Massachusetts, California, and Florida. The company is expanding its grow facilities in Florida and Arizona in preparation for increased wholesale operations.

Q4 Results

The company reported record-setting Q4 revenues of $42 million, a 55.4% year-over-year increase, and 18.5% sequential increase.

MedMen’s stores introduced delivery and curbside pickup in its California locations. The company also expanded it product and brand offerings in all of its stores.

The company enjoys a large retail footprint in California, which amounted to $25.2 million of its Q4 revenue. California sales were up 24.4% compared to last year’s quarter.

The company expects more overall growth in the California recreational cannabis market, and plans to continue expansion there. California is one of the largest cannabis markets in the world with $4.4 billion in cannabis sales estimated for 2021.

The company reported a gross profit of $19.7 million, a 79.1% increase from last year’s $11 million. MedMen operated at a net loss of $46.2 million due to the costs of opening new stores and expanding current facilities.

The company reported $11.9 million in cash, and total assets of $96.7 million. MedMen raised $100 million in capital since Q4 results via investments from Canadian Cannabis LP Tilray (NASDAQ:TLRY), and Serruya, a private equity firm.

Wall Street's Take

According to Wall Street, MedMen has a Hold consensus rating, based on two Holds assigned in the past three months. At C$0.39, the average MedMen price target implies 7.1% upside potential.


Multi-state operators (MSOs) stand to gain the most in the event of U.S. federal legalization.

MedMen operates 24 stores in five states, and has plans for expansion. The company continues to innovate its cannabis retail concept with home delivery and expanded brand offerings.

The company operates at a net loss, but has plenty of runway to complete its business vision.

MedMen’s stock trades near its target price, and is likely to uptrend.

Disclosure: At the time of publication, Alan Sumler had a position in MedMen and Tilray.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

MedMen Reports Record Q4 Revenues amid Pandemic Recovery

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email